QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:AGLE

Aeglea BioTherapeutics Stock Forecast, Price & News

$7.76
+0.51 (+7.03 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.47
Now: $7.76
$8.20
50-Day Range
$6.76
MA: $7.46
$7.98
52-Week Range
$3.50
Now: $7.76
$11.38
Volume369,149 shs
Average Volume233,440 shs
Market Capitalization$371.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Aeglea BioTherapeutics logo

Headlines

Aeglea (AGLE) Upgraded to Buy: Here's Why
December 30, 2020 |  finance.yahoo.com
Is AGLE A Good Stock To Buy Now According To Hedge Funds?
December 19, 2020 |  finance.yahoo.com
Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session
August 25, 2020 |  finance.yahoo.com
Aeglea BioTherapeutics Inc.
August 14, 2020 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGLE
CUSIPN/A
Phone512-942-2935
Employees87
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.89 million
Book Value$2.07 per share

Profitability

Net Income$-78,250,000.00

Miscellaneous

Market Cap$371.99 million
Next Earnings Date3/8/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

255th out of 1,971 stocks

Pharmaceutical Preparations Industry

117th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$7.76
+0.51 (+7.03 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aeglea BioTherapeutics (NASDAQ:AGLE) Frequently Asked Questions

Is Aeglea BioTherapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aeglea BioTherapeutics?

Wall Street analysts have given Aeglea BioTherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aeglea BioTherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aeglea BioTherapeutics' next earnings date?

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Aeglea BioTherapeutics
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its quarterly earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.10.
View Aeglea BioTherapeutics' earnings history
.

How has Aeglea BioTherapeutics' stock price been impacted by COVID-19?

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have increased by 44.2% and is now trading at $7.76.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AGLE?

4 brokerages have issued 1-year target prices for Aeglea BioTherapeutics' shares. Their forecasts range from $11.00 to $15.00. On average, they anticipate Aeglea BioTherapeutics' share price to reach $12.67 in the next year. This suggests a possible upside of 63.2% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aeglea BioTherapeutics' key executives?

Aeglea BioTherapeutics' management team includes the following people:
  • Dr. Anthony G. Quinn M.D., M.B Ch.B., Ph.D., FRCP, Pres, CEO & Director (Age 59, Pay $818.86k)
  • Dr. Leslie Sloan Ph.D., Chief Operating Officer (Age 50, Pay $516.84k)
  • Mr. Steven Weber, VP, Principal Accounting Officer & Corp. Controller (Age 44)
  • Joey Perrone, Sr. Director of Fin. & Investor Relations
  • Kelly Boothe Ph.D., Director of Corp. Communications
  • Mr. Eugene Sackett, VP of HR
  • Mr. Michael C. Hanley M.B.A., Chief Commercial Officer (Age 48)
  • Dr. Eric Bradford M.B.A., M.D., M.Sc., Chief Devel. Officer
  • Dr. Scott W. Rowlinson, VP of Research (Age 53)
  • Dr. F. Andrew Dorr, Exec. Officer (Age 68)

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aeglea BioTherapeutics' key competitors?

What other stocks do shareholders of Aeglea BioTherapeutics own?

When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (7.11%), BlackRock Inc. (6.76%), Dimensional Fund Advisors LP (1.13%), Dimensional Fund Advisors LP (1.13%), Northern Trust Corp (1.00%) and Assenagon Asset Management S.A. (0.34%).
View institutional ownership trends for Aeglea BioTherapeutics
.

Which major investors are selling Aeglea BioTherapeutics stock?

AGLE stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Renaissance Technologies LLC, Russell Investments Group Ltd., State of Wisconsin Investment Board, New York State Common Retirement Fund, GSA Capital Partners LLP, Barclays PLC, and Alliancebernstein L.P..
View insider buying and selling activity for Aeglea BioTherapeutics
or view top insider-selling stocks.

Which major investors are buying Aeglea BioTherapeutics stock?

AGLE stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Assenagon Asset Management S.A., Trexquant Investment LP, JPMorgan Chase & Co., Virtu Financial LLC, and Credit Suisse AG.
View insider buying and selling activity for Aeglea BioTherapeutics
or or view top insider-buying stocks.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $7.76.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics has a market capitalization of $371.99 million and generates $3.89 million in revenue each year. The biotechnology company earns $-78,250,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

Aeglea BioTherapeutics employs 87 workers across the globe.

What is Aeglea BioTherapeutics' official website?

The official website for Aeglea BioTherapeutics is www.aegleabio.com.

Where are Aeglea BioTherapeutics' headquarters?

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.